July, 2007

Sandy Dobbie becomes new chairman at Evolva

Sandy Dobbie has been elected new chairman at Evolva SA. The former chairman, Jean-Philippe Tripet, Managing Partner of Aravis Venture, will remain a member of the board of Evolva.

Sandy Dobbie has c. 30 years of international experience from the chemical industry, including several executive positions. With a PhD in Chemistry, the first part of his career was in R&D, manufacturing and marketing at Kelco (a subsidiary of Merck & Co.), where he became head of international operations. For more than 18 years, he has had board and management positions in US, UK and German companies, including two public companies in the UK. In 2001, he co-founded Cogency, a consulting company which provides specialist advice to Private Equity and Corporate clients investing in chemicals and pharmaceuticals. Sandy has an excellent track record in leading high-growth companies and in executing turnarounds and he has spearheaded several successful M&A transactions.

About Evolva. Evolva develops small molecule drugs based upon proprietary genetic chemistry technologies. Founded in 2004, it currently has pre-clinical stage compounds in the anti-infective and cardiovascular/metabolic disease space, and third party discovery collaborations in cancer, antiviral and immunomodulators. Evolva employs c. 70 people in Switzerland, India and Denmark. For more information see www.evolva.com.